The next generation of antibody-drug conjugates comes of age.
about
Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsLinkers Having a Crucial Role in Antibody-Drug ConjugatesImplications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesWorld Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.Production of unique immunotoxin cancer therapeutics in algal chloroplastsDevelopment of a recombinant antibody to target peptides and proteins to sialoadhesin-expressing macrophages.Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidatesTumor-targeting drug delivery of new-generation taxoids.Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Electrospray ionization-ion mobility spectrometry identified monoclonal antibodies that bind exclusively to either the monomeric or a dimeric form of prostate specific antigenExploration of fluorine chemistry at the multidisciplinary interface of chemistry and biology.In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.Novel antibody-based proteins for cancer immunotherapy.Selective formation of covalent protein heterodimers with an unnatural amino acid.Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion.7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.Biosimilar, biobetter and next generation therapeutic antibodies6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.Design principles for clinical efficacy of cancer nanomedicine: a look into the basics.Development of Antibody-Directed Therapies: Quo Vadis?Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).
P2860
Q24624489-197E1D7E-D07D-4AEF-929F-DC3F8F81A9F3Q26752763-B375D2E5-67DD-4795-8A4C-51AD8BAB18FFQ27007486-CACBEAF3-0948-4B75-A201-F756E00CCA74Q30414399-BE9051B4-A9C6-4688-B1EA-739AC57952B5Q34034756-BB3A9866-AB47-4B54-8BE5-2DCCB95EBDFEQ34663064-7C43029D-69E0-44D6-921E-4E62E5D83D8FQ35578028-D88BCBAB-60DF-4CAC-B308-8260539ED5F9Q35765100-4A45B85B-F760-4F0D-AC47-65BF520E950AQ35946005-33CD6E6C-582F-40EA-8B76-D8C271EFC861Q35992488-1725FAA5-5CFE-4FD9-AC91-47307EDF385DQ36145292-DF420118-9BD2-4E2D-AA08-BB3E5221B9A6Q37118460-3071BE50-9DF1-4F30-A229-4FB9E1BFCA9BQ37327321-823FD203-0387-4174-976C-F3107FC4C5A2Q37628646-3CE2CFC7-172B-4E24-A160-971E62B75AC2Q38161370-CB856221-41BD-4528-99DE-8FD0F246089DQ39570285-A6FC5CB0-14CB-48F7-A058-11108702F465Q41966465-53752278-72D8-4858-A825-09BEFF39AC9CQ42333450-36C4AE00-3A91-4790-BD3D-F57974146D20Q42333514-544C8E45-B430-49A2-BE7F-D0E6FDA9F373Q42337744-3DF1E9FC-B6F9-4E98-8984-56B72AADB95EQ42732007-20863444-ACF1-4D6B-8429-EEBB4AF2543CQ42732008-49D268AE-F652-48FF-B494-0D14D397C12EQ42768010-33456A2D-ED2C-4E21-B0D4-2BACECCDBFC0Q48228292-8C344F53-5B48-4CE3-AF26-8BA4641A9ED1Q52690917-107D318B-849C-46B8-8A6C-7D2D2B9D182AQ52704026-A73EE21A-95AE-4EC3-9162-58C831FFAF12
P2860
The next generation of antibody-drug conjugates comes of age.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The next generation of antibody-drug conjugates comes of age.
@en
The next generation of antibody-drug conjugates comes of age.
@nl
type
label
The next generation of antibody-drug conjugates comes of age.
@en
The next generation of antibody-drug conjugates comes of age.
@nl
prefLabel
The next generation of antibody-drug conjugates comes of age.
@en
The next generation of antibody-drug conjugates comes of age.
@nl
P2093
P1433
P1476
The next generation of antibody-drug conjugates comes of age.
@en
P2093
Alain Beck
Christian Bailly
Jean-François Haeuw
Liliane Goetsch
Nathalie Corvaïa
Thierry Wurch
P304
P577
2010-10-01T00:00:00Z